{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-221791","form_type":"8-K","ticker":"ENTA","cik":"0001177648","company_name":"ENANTA PHARMACEUTICALS INC","filed_at":"2025-09-29T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.497513+00:00","generated_at":"2026-05-17T05:22:11.810443+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"medium","headline":"Enanta reports positive Phase 2b topline data for zelicapavir in high-risk RSV adults","bullets":["Phase 2b study of zelicapavir (formerly EDP-938) met primary endpoint in high-risk adults with RSV.","Topline results announced September 29, 2025; detailed data presented in slide presentation.","Zelicapavir is an oral antiviral; no specific efficacy or safety numbers disclosed in the 8-K.","Positive outcome supports advancement; further details expected in future medical meetings."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-221791","json":"https://secwatch.observer/filing/0001193125-25-221791.json","markdown":"https://secwatch.observer/filing/0001193125-25-221791.md","text":"https://secwatch.observer/filing/0001193125-25-221791.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1177648/000119312525221791/0001193125-25-221791-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1177648/000119312525221791/d65423d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:22:11.810443+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}